Published in Cancer Res on September 08, 2009
The mutational landscape of prostate cancer. Eur Urol (2013) 2.14
Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer (2010) 1.18
Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol (2011) 1.00
Deregulation of HIF1-alpha and hypoxia-regulated pathways in hepatocellular carcinoma and corresponding non-malignant liver tissue--influence of a modulated host stroma on the prognosis of HCC. Langenbecks Arch Surg (2010) 0.93
SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer. Endocr Relat Cancer (2014) 0.89
Oncogenic functions of IGF1R and INSR in prostate cancer include enhanced tumor growth, cell migration and angiogenesis. Oncotarget (2014) 0.88
Proinflammatory cytokine interleukin-6 in prostate carcinogenesis. Am J Clin Exp Urol (2014) 0.87
Suppressor of cytokine signaling (SOCS) genes are silenced by DNA hypermethylation and histone deacetylation and regulate response to radiotherapy in cervical cancer cells. PLoS One (2015) 0.87
Monocyte chemoattractant protein-1 secreted by decidual stromal cells inhibits NK cells cytotoxicity by up-regulating expression of SOCS3. PLoS One (2012) 0.86
SOCS3 Deficiency in Myeloid Cells Promotes Tumor Development: Involvement of STAT3 Activation and Myeloid-Derived Suppressor Cells. Cancer Immunol Res (2015) 0.83
Cytokine induction of tumor necrosis factor receptor 2 is mediated by STAT3 in colon cancer cells. Mol Cancer Res (2011) 0.83
PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells. Oncotarget (2014) 0.82
The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinoma. BMC Cancer (2014) 0.82
In vivo identification of solar radiation-responsive gene network: role of the p38 stress-dependent kinase. PLoS One (2010) 0.81
The role of suppressors of cytokine signalling in human neoplasms. Mol Biol Int (2014) 0.81
miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer. Mol Endocrinol (2015) 0.81
The proinflammatory cytokine, IL-6, and its interference with bFGF signaling and PSMA in prostate cancer cells. Inflammation (2013) 0.81
Expression of interleukin-8 receptor CXCR2 and suppressor of cytokine signaling-3 in astrocytic tumors. Mol Med (2012) 0.80
PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer. Oncogene (2015) 0.79
Leishmania donovani prevents oxidative burst-mediated apoptosis of host macrophages through selective induction of suppressors of cytokine signaling (SOCS) proteins. J Biol Chem (2013) 0.79
MicroRNA signature characterizes primary tumors that metastasize in an esophageal adenocarcinoma rat model. PLoS One (2015) 0.79
Molecular signaling involving intrinsically disordered proteins in prostate cancer. Asian J Androl (2016) 0.77
Both IGF1R and INSR Knockdown Exert Antitumorigenic Effects in Prostate Cancer In Vitro and In Vivo. Mol Endocrinol (2015) 0.75
Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide. Oncotarget (2016) 0.75
[Diagnostic of prostate cancer: conventional and molecular or cell biological methods]. Pathologe (2009) 0.75
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell (2003) 3.92
p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol (2002) 3.80
p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet (2007) 3.19
Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature (2005) 3.09
TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A (2010) 2.72
c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell (2003) 2.59
SATB1 defines the developmental context for gene silencing by Xist in lymphoma and embryonic cells. Dev Cell (2009) 2.57
Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology (2011) 2.33
Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter. J Urol (2006) 2.29
Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell (2005) 2.26
The mutational landscape of prostate cancer. Eur Urol (2013) 2.14
Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder. Eur Urol (2009) 1.79
Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem (2005) 1.73
Derivation of nephrogenic adenomas from renal tubular cells in kidney-transplant recipients. N Engl J Med (2002) 1.69
Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging--initial results. Radiology (2007) 1.67
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med (2012) 1.67
Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol (2004) 1.65
Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. Gastroenterology (2009) 1.64
Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res (2006) 1.59
Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis. Cancer Res (2012) 1.58
Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res Ther (2008) 1.54
Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol (2012) 1.48
Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int J Cancer (2008) 1.48
The Fos-related antigen Fra-1 is an activator of bone matrix formation. EMBO J (2004) 1.46
Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes (2010) 1.44
Phylotype-level 16S rRNA analysis reveals new bacterial indicators of health state in acute murine colitis. ISME J (2012) 1.43
Translational regulation mechanisms of AP-1 proteins. Mutat Res (2009) 1.42
Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner. J Urol (2011) 1.41
Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol Cancer Ther (2011) 1.39
c-kit overexpression in chromophobe renal cell carcinoma is not associated with c-kit mutation of exons 9 and 11. Am J Surg Pathol (2005) 1.39
A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell (2013) 1.37
Cardiopulmonary resuscitation-associated major liver injury. Resuscitation (2007) 1.33
Late penile metastasis from primary bladder carcinoma. Urology (2003) 1.32
Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol (2004) 1.31
Tumor-associated macrophages promote invasion while retaining Fc-dependent anti-tumor function. J Immunol (2012) 1.31
Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer (2008) 1.30
JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther (2011) 1.29
Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res (2007) 1.27
Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res (2007) 1.26
CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int J Cancer (2004) 1.21
Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res (2008) 1.21
Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proc Natl Acad Sci U S A (2009) 1.20
CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer (2004) 1.19
Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. Stem Cells (2012) 1.19
[The first autochthonous case of subcutaneous dirofilariosis in Austria]. Wien Klin Wochenschr (2008) 1.18
Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer (2010) 1.18
The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood (2007) 1.18
Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis. Gastroenterology (2010) 1.17
Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis. Cell Cycle (2011) 1.17
Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci U S A (2008) 1.17
Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis. Am J Clin Pathol (2012) 1.16
Oxidative stress-related aging: A role for prostate cancer? Biochim Biophys Acta (2008) 1.16
Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood (2008) 1.16
Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proc Natl Acad Sci U S A (2010) 1.15
Renal tumour size measured radiologically before surgery is an unreliable variable for predicting histopathological features: benign tumours are not necessarily small. BJU Int (2007) 1.15
Frozen section analysis-guided organ-sparing approach in testicular tumors: technique, feasibility, and long-term results. Urology (2003) 1.14
The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate (2011) 1.13
Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study. Mod Pathol (2005) 1.12
Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol (2008) 1.12
Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res (2007) 1.12
p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res (2005) 1.10
JunB inhibits proliferation and transformation in B-lymphoid cells. Blood (2003) 1.10
Androgen receptors in prostate cancer. J Urol (2003) 1.07
Dabigatran pharmacokinetics--implications for treatment. Am J Kidney Dis (2013) 1.07
Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol (2003) 1.07
A novel approach to energy ablative therapy of small renal tumours: laparoscopic high-intensity focused ultrasound. Eur Urol (2007) 1.07
Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells. EMBO Mol Med (2013) 1.07
Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Prostate (2004) 1.06
Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. Endocr Relat Cancer (2012) 1.06
Expression of kidney-specific cadherin distinguishes chromophobe renal cell carcinoma from renal oncocytoma. Hum Pathol (2005) 1.05
The different functions of Stat5 and chromatin alteration through Stat5 proteins. Front Biosci (2008) 1.05
Occurrence of polyorchidism in a young man. Urology (2002) 1.05
JunD regulates lymphocyte proliferation and T helper cell cytokine expression. EMBO J (2004) 1.04
Crucial function of histone deacetylase 1 for differentiation of teratomas in mice and humans. EMBO J (2010) 1.03
PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. Am J Pathol (2012) 1.02
Epidermal JunB represses G-CSF transcription and affects haematopoiesis and bone formation. Nat Cell Biol (2008) 1.01
Disruption of the growth hormone--signal transducer and activator of transcription 5--insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis. Hepatology (2010) 1.00
Histone acetyl transferase 1 is essential for mammalian development, genome stability, and the processing of newly synthesized histones H3 and H4. PLoS Genet (2013) 0.99
'Skipping' is still a problem with radiofrequency ablation of small renal tumours. BJU Int (2007) 0.99
Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol Cell Endocrinol (2002) 0.98
Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol Ther (2009) 0.98
The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol (2005) 0.98
Long-term results of laparoscopic retroperitoneal lymph node dissection: a single-center 10-year experience. Urology (2004) 0.97
Growth-hormone-induced signal transducer and activator of transcription 5 signaling causes gigantism, inflammation, and premature death but protects mice from aggressive liver cancer. Hepatology (2012) 0.97
The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J Pathol (2004) 0.96
Response to sublethal heat treatment of prostatic tumor cells and of prostatic tumor infiltrating T-cells. Prostate (2004) 0.96
Sphingosine-1-phosphate receptor type-1 agonism impairs blood dendritic cell chemotaxis and skin dendritic cell migration to lymph nodes under inflammatory conditions. Int Immunol (2008) 0.96
The dark and the bright side of Stat3: proto-oncogene and tumor-suppressor. Front Biosci (Landmark Ed) (2009) 0.96